

## **II. REMARKS**

### **A. Status of the Claims**

Claims 1-8 were originally filed in the case, and are currently pending and presented for consideration.


### **B. Response to Restriction Requirement**

In response to the Restriction Requirement imposed by the Examiner, Applicants elect, without traverse, the Group I invention (claims 1-5 and 8), drawn to methods of enhancing death receptor-induced apoptosis via inhibiting MUC1 via antisense or siRNA compounds.

As noted in the Office Communication, claim 1 links inventions I-III. Applicants understand that upon the allowability of the linking claim, the restriction requirement as to the linked inventions shall be withdrawn and any claim depending from or otherwise requiring all the limitations of the allowable linking claim will be rejoined and fully examined for patentability in accordance with 37 C.F.R. §1.104.

Applicants believe that the foregoing is a complete reply to the Office Communication mailed on January 9, 2009. The Examiner is invited to contact the undersigned attorney at (512) 536-5639 with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,



Monica A. De La Paz  
Reg. No. 54,662

Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
512.474.5201 (telephone)  
512.536.4598 (fax)

Date: April 7, 2009